<DOC>
	<DOCNO>NCT00002748</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-2 person 's neuroblastoma cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness use interleukin-2 gene-modified neuroblastoma cell treat child refractory recurrent neuroblastoma .</brief_summary>
	<brief_title>Gene Therapy Treating Children With Refractory Recurrent Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety child recurrent neuroblastoma two weekly subcutaneous injection autologous , partially HLA-matched allogeneic , neuroblastoma cell modify insertion interleukin-2 gene introduce retroviral vector . II . Determine whether multiple histocompatibility-restricted unrestricted antitumor immune response induce treatment cell dose require produce effect . III . Obtain preliminary data antitumor effect regimen . OUTLINE : Autologous partially HLA-matched allogeneic neuroblastoma cell transduce human gene interleukin-2 production . Patients receive subcutaneous injection gene-modified cell day 1 8 , second injection contain 10 time cell first injection . After 3-4 week rest , stable respond patient may receive additional weekly injection second dose . Cohorts 3-6 patient enter increase cell dos maximum tolerate dose estimate . Multiple injection site may use high cell-dose level . Patients follow every week 6 week , every week 6 week , monthly 1 year . Additional visit may require clinically indicate . PROJECTED ACCRUAL : Approximately 12 patient enter autologous partially HLA-matched allogeneic tumor cell treatment group . Accrual expect require 4 year autologous tumor cell group 2 year partially HLA-matched allogenic tumor cell group .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven high risk neuroblastoma completion plan primary therapy No rapidly progress disease Allogeneic transduce cell line available Demonstrated production least 150 picograms interleukin2 per 10 6th cell per day PATIENT CHARACTERISTICS : Age : Under 21 diagnosis Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : ( unless marrow replace tumor ) Absolute neutrophil count great 500/mm3 Platelet count great 50,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST great 2 time normal PT normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 80 mL/min Urinalysis normal Metabolic : Electrolytes ( include calcium , phosphate ) normal Glucose normal Weight great 10th percentile age Albumin great 3 g/dL Other : No active infection HIV negative Not pregnant nursing PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior chemotherapy No concurrent antibiotic except prophylactic trimethoprim/sulfamethoxazole No concurrent drug analgesic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>